u/fabio_lehtinen

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

This. A quoted lead time that holds is worth more than a fast one that does not.

Contemporaneous notes matter most in exactly the situations where people are least inclined to write them. Memory reorganises a bad fortnight into a tidier story with a clearer villain.

Push back: that is a taper schedule aimed at another member and this board does not host those.

The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.

a non-peptide agonist does not degrade the way a peptide does

Adding the standing caveat — unapproved, and research material is not for human use.

Same conditions each time for the weigh-in?

Push back: comparing a July transit with a February one on the same lane is not a comparison.

Cosigning on missed weeks. Leaving them blank makes the whole series misleading.

That reads as advice to stop, which is not something anyone here should be offering.

Disagreeing with this bit: stretching and reducing are different things and the post treats them as one.

There is very little published guidance on stopping specifically, which is exactly why board consensus here should carry less weight than usual and a clinician conversation should carry more.

the same name covers several different molecules in this space

Push back: comparing a July transit with a February one on the same lane is not a comparison.

two identical orders a week apart is the cheapest experiment available

Agreed — somebody is at exactly the point you were at, reading this, and it will land differently for them than any success story.

Read both programme names carefully after mixing them up in a comment and being politely corrected.

daily dosing changes adherence in both directions

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

small molecule, not a peptide, and that changes everything about it

Correcting myself: that was a phase 2 readout and I described it as phase 3.

How many shipments does your figure cover?

How fast was the escalation? That is usually the variable that explains the reports.

a lot of the confident posting here is extrapolation

Stretched from seven days to ten to twelve over four months. Appetite told me where the limit was each time.

A1c reflects average glycaemia over roughly the preceding three months, weighted towards the most recent weeks. It cannot show variability and it lags any change you make.

money lost to a shop with nothing on file is the recurring story

Agreed — and being harder on yourself than you would be on somebody else posting the same thing is the pattern here.

identity testing on a small molecule is a different analytical problem

Yes — log what happened rather than what you intended. My retrospective entries were quietly wrong every time.

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

Not convinced that was avoidable. Some of this is genuinely bad luck and treating everything as a lesson is its own trap.

Push back: that is a taper schedule aimed at another member and this board does not host those.

phase 2 data only, and people quote it like it is a label

the energy-expenditure story is mechanistically interesting and clinically unproven

Are you tracking heart rate at all?

Annotation is what makes a log survive contact with your future self. A single note beside an unusual week saves an hour of puzzled reconstruction later.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

Net peptide content on the certificate was well below the purity figure and both were honest. Chemistry, not deception.